Simple mathematical data processing method for the determination of sever overlapped spectra of linagliptin and empagliflozin in their pure forms and pharmaceutical formulation: Fourier self deconvulated method

(A) Deconvulated spectra of LIN(2–12 μg/ml) determined at 232 nm zero-crossing point of EMP deconvulated spectrum, (B) Deconvulated spectra of EMP (5–30 μg/ml) determined at 239 nm zero-crossing point of LIN deconvulated spectrum. [Display omitted] •Linagliptin and empagliflozin are used in treatment of type II diabetes mellitus.•Fourier self deconvulated spectrophotometric method was developed for qualitative analysis of linagliptin and empagliflozin.•The developed method determined the cited drugs in their pharmaceutical formulation.•The developed method was simple, economic and accurate.•Applied method was validated according to ICH guidelines and compared to the reported method. A new and simple spectrophotometric method was developed for the simultaneous determination of a new antidiabetic mixture of linagliptin and empagliflozin namely fourier self deconvulated method. The developed method based on minimal mathematical data processing on the zero order spectrum for solving sever overlapping spectra of the mentioned drugs in their pure forms and pharmaceutical dosage form. The zero order spectra of linagliptin and empagliflozin were deconvulated using Fourier transforms function. The peak amplitudes at 232 nm were selected for linagliptin and at 239 nm for empagliflozin. The constructed calibration graphs were linear over the range (5–30 µg/mL) and (2–12 µg/mL) for empagliflozin and linagliptin, respectively. The adopted method was simple, accurate, precise and validated according to the ICH guidelines.